ReviewJournal of immunology (Baltimore, Md. : 1950)2016
From IgE to Omalizumab.
Review in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials.BMC pediatrics · 2026Pooled it
- Efficacy and safety of different doses of ligelizumab in patients with chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials with GRADE evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Histamine-releasing factor enhances food allergy.The Journal of clinical investigation · 2017Trial
- Article
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Efficacy predictions for omalizumab treatment based on basophil CD203c expression in patients with allergic rhinitis by basophil activation test -- a real-life, pilot study.The World Allergy Organization journal · 2026Article
- Prevalence and association of elevated total serum IgE levels with ICU admissions and poor asthma control: a retrospective study in a tertiary hospital in Saudi Arabia.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma.The journal of allergy and clinical immunology. Global · 2025Article
- Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI.The journal of allergy and clinical immunology. Global · 2025Article
- Allosteric inhibition of IgE-FcεRI interactions by simultaneous targeting of IgE F(ab')2 epitopes.Communications biology · 2024Article
- Article
- Article
- Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.American journal of clinical dermatology · 2024Review
- Histamine-releasing factor in severe asthma and rhinovirus-associated asthma exacerbation.The Journal of allergy and clinical immunology · 2023Article
- Differentially expressed microRNAs in peripheral blood cell are associated with downregulated expression of IgE in nonallergic childhood asthma.Scientific reports · 2023Article
- Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Regulation of Syk activity by antiviral adaptor MAVS in FcεRI signaling pathway.Frontiers in allergy · 2023Article
- Pericytes: The lung-forgotten cell type.Frontiers in physiology · 2023Review
- Biologics and airway remodeling in severe asthma.Allergy · 2022Review
- Bullous Pemphygoid and Novel Therapeutic Approaches.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
IgE is the least abundant Ig isotype, yet it plays a critical role in allergic reactions and host protection from helminth infection. Although IgE was discovered 50 years ago, the ultimate evidence for its role in human allergic diseases was obtained by the efficacy of anti-IgE therapy in many clinical trials on asthma and other allergic diseases. Beginning from the discovery of IgE 50 y ago, followed by studies of IgE receptors and activation mechanisms, this review provides a historic perspective of allergy research that has led to the development of anti-IgE therapy and other strategies targeting IgE and its receptors. Current IgE studies toward future precision medicine are also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.